Form 4: Rocket Pharmaceuticals Director Granted 30,000 Restricted Stock Units

Elisabeth Bjork, a Director at Rocket Pharmaceuticals, Inc., was granted 30,000 Restricted Stock Units (RSUs) as part of her compensation.

Summary

• Elisabeth Bjork, a Director of Rocket Pharmaceuticals, Inc. (RCKT), was granted 30,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 18, 2025.
• The RSUs were acquired at a price of $0 per unit, which is typical for equity compensation grants.
• Following this transaction, Elisabeth Bjork beneficially owns 30,000 shares directly.
• These RSUs are scheduled to vest in full on June 18, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it represents a standard compensation event, it aligns the director's interests with the company's long-term performance, which is generally viewed favorably by investors.

Positives

• The grant of Restricted Stock Units (RSUs) to a director helps align their long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in the biotechnology sector.

Negatives

• The issuance of new shares upon vesting of RSUs can lead to minor dilution for existing shareholders, although this is a common and expected aspect of equity compensation plans.

Future Outlook

The granted Restricted Stock Units (RSUs) are set to vest in full on June 18, 2026, indicating a future milestone for this compensation.

Industry Context

The grant of Restricted Stock Units (RSUs) to a director is a common and standard practice within the biotechnology and pharmaceutical industries for compensating board members and aligning their interests with the company's long-term performance and shareholder value.

Related Party Transactions

• Elisabeth Bjork, a Director of Rocket Pharmaceuticals, Inc., received 30,000 Restricted Stock Units (RSUs) as compensation, which constitutes a transaction between the company and a related party (board member).

Stakeholder Impact

• Shareholders: The grant of RSUs may result in minor future dilution upon vesting, but it also serves to align the director's interests with shareholder value creation.
• Employees: This specific filing does not directly impact the broader employee base, but it reflects standard compensation practices for leadership.

Next Steps

• The 30,000 Restricted Stock Units (RSUs) granted to Elisabeth Bjork are expected to vest in full on June 18, 2026.

Key Dates

Recommendation

Keywords

Rocket Pharmaceuticals, RCKT, Restricted Stock Units, RSUs, Insider Transaction, SEC Form 4, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals